Sentiment Trading

Axsome Therapeutics reported a loss in Q1 2025, but exceeded revenue expectations with a 62% top-line growth, driven by its CNS portfolio expansion, and its stock performance remains resilient despite financial losses.

Axsome Therapeutics reported a 60% increase in Q1 revenue, beating expectations, despite a net loss, and is awaiting a potential FDA approval for its fibromyalgia treatment, AXS-14, in Q2 2025.

Axsome Therapeutics Inc. reported a 60% revenue growth in Q1 2025, exceeding expectations despite a reported loss, and is poised for future success with its strategic CNS portfolio expansion.